INDIANAPOLIS, INDIANAPOINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “DOT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, announced the closing of its previously announced underwritten public offering of 13,900,000 ordinary shares at a public offering price of $9.00 per share. The Company’s gross proceeds from the offering, before deduction of underwriting discounts and commissions and other estimated offering costs, were approximately $125 million.

Piper Sandler and Guggenheim Securities, LLC acted as co-bookrunners of the offering. Oppenheimer & Co. acted as lead tender.

POINT intends to use the net proceeds of the proposed offering, together with its existing cash, cash equivalents and investments, to fund clinical and preclinical research and development programs, pre-commercialization activities, as well as for working capital and other general business needs.

The securities are offered by POINT pursuant to a registration statement on Form S-3 previously filed and declared effective by the Security and Exchange Commission (‘SECOND‘). A prospectus supplement and accompanying prospectus relating to the proposed offering have been filed with the SECOND and is available for free at DRY website at Copies of the prospectus supplement and accompanying prospectus relating to these securities may also be obtained free of charge from:

Piper Sandler & Co.Attention: Prospectus Service, 800 Mail NicolletJ12S03, Minneapolis, Minnesota 55402, by phone at (800) 747-3924 or by email at [email protected]

Guggenheim Securities, LLCAttention: Equity Syndicate Department, 330 Madison Avenue8th floor, New York, NY 10017, by phone at (212) 518-9544 or by email at [email protected]

Oppenheimer & Co.Attention: Trade Union Prospectus Service, 85 wide street26th floor, New York, NY 10004, or by phone at (212) 667-8055, or by email at [email protected]

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities of POINT, and there will be no sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or territory.

About POINT Biopharma Global Inc.

POINT Biopharma Global Inc. is a global radiopharmaceutical company building a platform for the clinical development and commercialization of cancer-fighting radioligands. POINT aims to transform precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a state-of-the-art pipeline, in-house manufacturing capabilities and a secure supply of rare medical isotopes like actinium-225 (225Ac) and lutetium-177 (177 Lu). POINT’s active clinical trials include FRONTIER, the Phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activating protein-? (FAP-?) and SPLASH, the Phase 3 trial for PNT2002 for people with metastatic castration-resistant prostate cancer (mCRPC) after second-line hormone therapy.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some instances, you may identify forward-looking statements by the following words: “may”, “will, ‘ ‘could’, ‘do’, ‘should’, ‘expect’, ‘intend’, ‘plan’, ‘anticipate’, ‘believe’, ‘estimate’, ‘predict’ ‘project’ ‘potential’, ‘continuing’, ‘ongoing’ or the negative form of these terms or other comparable terms, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from the information expressed or implied by these forward-looking statements. Although we believe we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that such statements are based on a combination of facts and factors currently known to us and our projections for the future, about of which we cannot be certain. We cannot assure you that the forward-looking statements contained in this press release will prove to be accurate. These forward-looking statements are subject to a number of important risks and uncertainties that could cause actual results to differ materially from expected results, including, among other things, changes resulting from market conditions or other reasons. , the risk that the offering may not be consummated, risks relating to COVID-19, the ability to maintain the listing of POINT’s common stock on NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be affected by other economic, business and/or competitive factors and other risks and uncertainties, including those described at DOT Annual Report on Form 10-K filed with the SECOND on March 25, 2022 and subsequent filings with the SECOND. Most of these factors are beyond POINT’s control and are difficult to predict. In addition, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the material uncertainties in these forward-looking statements, you should not consider these statements to be a representation or warranty by us or anyone else that we will achieve our goals and plans within a specified time frame, or at all. The forward-looking statements contained in this press release represent our opinions as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may choose to update these forward-looking statements at some time in the future, we currently have no intention of doing so except as required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.



T: 1-833-544-2637

POINT Biopharma Global Inc.

4850 West 78th Street.

Indianapolis, Indiana 46268

United States